Takeda Pharmaceutical Company Limited (TAK): what the price assumes

In the published model solve dated 2026-Q2, anchored at $16.72, Takeda Pharmaceutical Company Limited (TAK) is priced for +17.4% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-11.

Generated: 2026-08-10 · Exported: 2026-08-12 · Source: https://boothcheck.com/report/TAK

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 12: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~10.1pp (computed at the 7% minimum rate; the CAPM rate 6.3% sits below it).

Reconcile: at the x-ray's 9.3% required return this reads ~7.9 years; the models below use their own rates.

How unusual the bet is: elevated

Valuation X-Ray

The price is justified by relative-multiple and growth-DCF; asset-based/earnings-power land below the price.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Relative, Growth Families that call it expensive: Asset, Earnings

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 6.8%); the inversion above states its own rate.

Per-Model Detail (n=15)

Solvency

Bullet Takeaways

• Takeda trades at roughly 0.57 times book value into a twelve-month window with three planned launches, oveporexton (narcolepsy, filed in the U.S., Japan, and China), rusfertide (polycythemia vera), and zasocitinib (psoriasis), while the price embeds only about 5% annual operating growth.

• The biggest risk is the levered transition: about $22.0 billion of net debt at roughly 2 times interest coverage, FY2026 core operating profit guided down 5% to 8% at constant currency, and continued Vyvanse generic erosion that has outlasted two of management's own end-date calls.

• Watch the oveporexton and rusfertide launches targeted for the second half of 2026, new CEO Julie Kim's first quarterly reports after taking office in June 2026, and whether Entyvio holds its roughly 4% constant-currency growth guidance.

Bull Case

The market is pricing Takeda as a pharma in managed decline: today's price embeds company-wide operating growth of only about 5.2% a year for five years, an assumption our framework reads as comfortably within the plausible range, and the stock changes hands at roughly 0.57 times book value, with $29.29 of book behind each $16.57 share. Set that against what the company is actually doing and the gap is the thesis. Fiscal 2025 closed with core revenue of 4.5 trillion yen (about $28.3 billion) and core operating profit of 1.17 trillion yen, and management called the year pivotal, with what it describes as the most robust late-stage pipeline in the company's history.

Three launches inside roughly a year is the concrete version of that claim. Oveporexton, for narcolepsy type 1, has regulatory applications submitted in the United States, Japan, and China with launch targeted for the second half of 2026; rusfertide, for polycythemia vera, targets the same window; zasocitinib, for psoriasis, follows in the first half of 2027. A market pricing five percent growth is implicitly assigning little value to all three. If even one launches at scale, the growth assumption embedded in the price gets revised from below, which is the cheapest kind of upside: the bar is on the floor.

The transition costs are real and the bull case should not pretend otherwise. Vyvanse generics have been grinding down U.S. revenue, and FY2026 guidance accepts a core operating profit decline of 5% to 8% at constant currency as the company reinvests in the launch wave. But the shareholder is being paid to wait: the dividend was raised alongside the FY2025 results, the share count has been essentially flat for four years, and the company generates positive free cash flow through the trough. A new chief executive, Julie Kim, took office in June 2026 after running the U.S. business, and continuity of the launch plan was the explicit centerpiece of her first outlook. Buying a below-book pharma at the exact moment its patent-cliff years end and its launch years begin is the whole trade.

Bear Case

Start with how the capital has been deployed and what it has returned. Takeda carries about $22.0 billion of net debt, the residue of a decade of acquisition-led strategy, and interest coverage now runs at roughly 2 times operating income. Against that leverage, the accounting bottom line shows almost nothing: trailing reported earnings of $0.11 per share and a return on equity of 0.4%. Management's core measures run far ahead of the reported figures, and the FY2026 guidance itself concedes the wedge, with reported EPS guided to 104.26 yen against core EPS of 472 yen, a gap management attributes to higher finance costs, a normalized tax rate, and reinvestment. A company whose statutory profits are this thin, this many years after the deals that built it, is a company still paying for its own strategy.

The dividend policy sharpens the concern. The board raised the dividend alongside FY2025 results even as it guided core operating profit down 5% to 8% at constant currency for FY2026. Paying a growing dividend out of a declining profit base, on top of a levered balance sheet, is a commitment that narrows the room for error if any launch slips. And the pattern of promises deserves scrutiny: the company signaled that fiscal 2024 would be the last year of major Vyvanse generic damage, then said the same of fiscal 2025. Entyvio, the largest growth brand, grew 4.2% at constant currency in FY2025 against a 6% forecast, and management expects only about 4% again in FY2026 as pricing pressure and competition intensify.

Leadership adds a genuine unknown at exactly the wrong moment. Christophe Weber retired in June 2026 after twelve years, and Julie Kim assumed the chief executive role days before the launch wave the entire equity story depends on. The three launches, oveporexton, rusfertide, and zasocitinib, are binary in the way pharmaceutical launches always are, and the own 20-F flags the debt load, Entyvio pricing, and patent cliffs as the standing risks. The stock looks cheap on book value, but the excess-return arithmetic explains the discount without any mispricing: equity that earns 0.4% on its book is priced below that book for a reason. The bear case is simply that the discount is deserved until the launches prove otherwise.

Valuation

Worked backward, the price is a modest ask. At $16.57 (July 10, 2026), the market is paying roughly 24 times company-wide operating income on our basis, which unwinds to operating growth of about 5.2% a year over five years, an assumption our comparison set reads as within the plausible range for a business like this, though the comparison data behind that label is limited and the read is best treated directionally. For a company guiding three product launches into the next twelve months, five percent is not an heroic requirement. That is the single most useful fact about this price.

The disagreement among the methods is wide, and the pattern explains itself. Only the forward-looking cash-flow approaches reach the current price; the asset-based, earnings-power, and trailing peer-multiple reads all sit far below it. The driver is the near-empty reported income statement: trailing earnings of $0.11 per share and a 0.4% return on equity mean any method that capitalizes what the company has statutorily earned finds very little to capitalize, even with $29.29 of book value per share sitting under a $16.57 price. Management's core measures tell the other half, with FY2025 core operating profit of 1.17 trillion yen on core revenue of 4.5 trillion yen; the space between the reported and core figures is where this valuation argument actually lives, and the methods that trust forward cash flows are implicitly siding with the core view.

The balance sheet sets the terms of the bet. Net debt of about $22.0 billion runs against interest coverage of roughly 2 times operating income, the share count has been flat (up about 0.3% a year over four years), and the company is not burning cash. That leverage is why the launch calendar matters more here than at an unlevered pharma: the equity is a thin slice of a large enterprise, and each of oveporexton, rusfertide, and zasocitinib moves the slice disproportionately. The price asks little; the balance sheet forgives little. Those two facts, held together, are the valuation.

Catalysts

The launch calendar is the dominant catalyst set. Oveporexton, for narcolepsy type 1, has regulatory applications submitted in the United States, Japan, and China, with launch targeted for the second half of 2026; rusfertide, for polycythemia vera, targets the same window; and zasocitinib, for psoriasis, is slated for the first half of 2027. Approval decisions and early launch metrics on the first two will arrive within the next two to three quarters, and each is an event the current price, which embeds only modest growth, has room to respond to in either direction.

Leadership and guidance frame the same period. Julie Kim formally became chief executive on June 24, 2026, following the annual general meeting at which Christophe Weber retired after twelve years. Her first full fiscal year carries guidance of FY2026 revenue of 4,640 billion yen, up 3.0% as reported, with core revenue declining low single digits at constant currency and core operating profit down 5% to 8% at constant currency, reflecting reinvestment into the launch assets plus higher finance costs. The first quarterly report under the new guidance, expected in late July on the company's usual cadence, will show whether Vyvanse generic erosion is finally decelerating and whether Entyvio is tracking its roughly 4% constant-currency growth expectation.

The dividend and the balance sheet are the quieter watch items. The board raised the dividend alongside FY2025 results, extending the payout commitment into a down-profit year, and the 20-F filed in June 2026 lists the debt load, Entyvio pricing pressure, and patent cliffs among the standing risk factors. Deleveraging progress against the roughly $22 billion net debt position is the metric that converts launch success into equity value fastest.

Peer Cohorts (Per Segment, With Filing Citations)

Core business (reported)

• GILD (GILEAD SCIENCES, INC.)
• FY2025 10-K: …quarter, we may continue to see fluctuations in our earnings and a mismatch between prescription demand for our products and our revenues. 18 We face significant competition from global pharmaceutical and biotechnology companies, specialized pharmaceutical firms and generic drug manufacturers. New branded or generic…
• FY2025 10-K: …we maintain a strong workplace culture that is attractive to employees. In addition, competition for qualified personnel in the biopharmaceutical field is intense, and there is a limited pool of qualified potential employees to recruit. We face competition for personnel from other companies, universities, public and…
• SYK (STRYKER CORP)
• FY2025 10-K: …medical products and services. Such downward pricing pressures from any or all of these payers may result in an adverse effect on our business, results of operations, financial condition and cash flows. We have also reduced prices for certain products due to increased competition and if we further reduce prices, we…
• FY2025 10-K: …products restricts competitors from duplicating these unique designs and features. We seek to obtain patent protection on our products whenever appropriate for protecting our competitive advantage. On December 31, 2025 we owned approximately 5,600 United States patents and approximately 9,000 patents in other…
• MDT (Medtronic plc)
• FY2025 10-K: …current environment of managed care, economically motivated 10 Table of Content customers, consolidation among healthcare providers, increased competition, declining reimbursement rates, and national and provincial tender pricing, competitively priced product offerings are essential to our business. In order to…
• FY2025 10-K: …operating profit in the budget and forecasting process and to monitor budget and forecast variances versus actual when assessing segment performance and allocating capital resources to each segment. The accounting policies of the segments are the same as those described in Note 1. Certain depreciable assets may be…
• MMM (3M COMPANY)
• FY2025 10-K: …of the Company's Health Care business, including the risk that the expected benefits will not be realized; the risk that the costs or dis-synergies will exceed the anticipated amounts; potential impacts on the Company's relationships with its customers, suppliers, employees, regulators and other counterparties; the…
• FY2025 10-K: …within the Notes to Consolidated Financial Statements. 13 Table of Contents Risks Related to Our Products and Customer Preferences * The Company's results are affected by competitive conditions and customer preferences. Demand for the Company's products, which impacts revenue and profit margins, is affected by, among…
• AMGN (Amgen Inc.)
• FY2025 10-K: …31, 2025, 2024 and 2023, we had product sales to three customers that individually accounted for more than 10% of total revenues. For the year ended December 31, 2025, on a combined basis, these customers accounted for 77 % of total gross revenues as shown in the following table. Certain information with respect to…
• FY2025 10-K: …can enhance such advantages. These advantages may make it difficult for us to compete with them successfully to discover, develop and market new products and for our current products to compete with new products or new product indications they may bring to market. As a result, our products have been competing and may…
• GSK (GSK plc)
• FY2025 20-F: Notes to the financial statements continued 6. Turnover and segment information continued Net operating assets by segment 2025 £m 2024 £m Commercial Operations 13,286 12,501 Research and Development 9,637 7,459 Segment net operating assets 22,923 19,960 Corporate and other unallocated net operating assets 1,099 43 Net…
• FY2025 20-F: Group turnover by business Specialty Medicines (S) £13.5bn AER growth +14% CER growth +17% Vaccines (V) £9.2bn AER stable -% CER growth +2% General Medicines (G) £10.0bn AER decline -4% CER decline -1% S G V Group turnover by geographic region US Int US £16.9bn AER growth +3% CER growth +6% Europe £7.5bn AER growth…
• THC (TENET HEALTHCARE CORP)
• FY2025 10-K: …of need in any jurisdiction where they are required, or if any jurisdiction will eliminate or alter its certificate of need requirements in a manner that will increase competition and, thereby, affect our competitive position. In those states that do not have certificate of need requirements or that do not require…
• FY2025 10-K: …healthcare consumers are able to access performance data on quality measures and patient satisfaction, as well as pricing information for services, to compare competing providers. In addition, the No Surprises Act requires providers to send to health plans of insured patients and to uninsured patients good faith…
• BDX (BECTON DICKINSON & CO)
• FY2025 10-K: …acquisition date, as well as the impact from amortization of intangibles acquired in the transaction which occurred on September 3, 2024. 45 Table of Contents The favorable impact on gross margin from specified items in 2024 compared with 2023 primarily reflected a favorable comparison to specified items recorded in…
• FY2025 10-K: …of Contents Notes to Consolidated Financial Statements - (Continued) Becton, Dickinson and Company The following tables include the significant expenses by segment that are regularly provided to the CODM and a reconciliation of segment operating income to Income from Continuing Operations before Income Taxes. Fiscal…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.